# Department of Pharmacology
# 2023 - 2024 Seminar Series

## "Oxylipins reveal new pharmacological targets for the prevention of cardiovascular disease"

Cardiovascular disease is the number one cause of death globally and while seminal discoveries have identified several therapeutic targets to limit platelet activation, thrombosis remains a significant health concern. Although the platelet forms a number of oxidized lipids (oxylipins) through oxidation of free fatty acids by the enzyme 12-lipoxygenase, little is known about how many of these oxylipins function to regulate platelet activity. My lab has elucidated the signaling pathways for several of these oxylipins in order to develop novel therapeutic approaches to inhibit platelet activity and prevent occlusive thrombotic events that result in myocardial infarction and stroke.


**Michael Holinstat, Ph.D., FAHA**

Professor of Pharmacology
University of Michigan


**March 26th, 2024**
**4:00 PM**
**1220 MRB III**

**Host: Claus Schneider**

VANDERBILT
School *of* Medicine
Basic Sciences